Abstract
Lung cancer is the leading cause of cancer death worldwide and non-small cell lung carcinoma (NSCLC) represents 85% of newly diagnosed lung cancers. The high mortality rate of lung cancer is due in part to the lack of effective treatment options for advanced disease. A major limitation in the development of effective treatment options is our incomplete understanding of NSCLC metabolism at a molecular level, especially lipids. Improvements in mass spectrometry combined with our untargeted assignment tool SMIRFE enable the systematic and less biased examination of NSCLC lipid metabolism.
Lipids were extracted from paired tumorous and non-tumorous lung tissue samples from 86 patients with suspected resectable stage I or IIa primary NSCLC and were analyzed using ultra-high resolution Fourier transform mass spectrometry. Pathological examination of the samples revealed that the majority of the samples were primary NSCLC; however, the disease group does include examples of metastases of other cancers and several granulomas. Information-content-informed (ICI) Kendall tau correlation analysis revealed correlation and co-occurrence patterns consistent with significant changes in lipid profiles between disease and non-disease samples. Lipids assigned using the program SMIRFE (Mitchell et al., 2019) were analyzed for differential abundance, followed by machine learning to classify the SMIRFE formula assignments into lipid categories. At the lipid category level, sterol abundances were consistently higher in diseased versus non-diseased lung tissues at statistically significant levels.
The statistically significant increase in sterol abundances in primary NSCLC compared with non-cancerous lung tissue suggests for treatment of primary NSCLC a possible therapeutic role for statins and nitrogenous bisphosphonates, pharmaceuticals that inhibit endogenous sterol biosynthesis. This hypothesis is consistent with previous epidemiological studies that have identified a therapeutic role for statins in the treatment of NSCLC but were unable to identify a molecular mechanism for this effect. Additionally, the majority of the consistently increased sterol abundances belong to the sterol ester subcategory, suggesting increased SCD1 and ACAT1 activity. SCD1 expression is a known negative prognostic indicator for survival in NSCLC. In our study, a large fraction of the NSCLC samples displayed this phenotype; however, SCD1 mutants would be unexpected in all of these samples. This suggests that this metabolic phenotype may be shared across multiple genetic subtypes of NSCLC. Thus, inhibitors of SCD1 and other enzymes involved in the production of this metabolic phenotype could have utility in the treatment of many genetic subtypes of NSCLC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was supported in part by grants NSF 1419282 (PI Moseley), NSF 2020026 (PI Moseley), NIH 1P01CA163223-01A1 (PD Lane), 1U24DK097215-01A1 (PD Higashi), and P30 CA177558 (B.M. Evers, PI).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All samples were collected under a University of Louisville approved Internal Review Board (IRB) protocol or University of Kentucky IRB protocol and written informed consent was obtained from all subjects prior to inclusion in the study (Sellers et al., 2015).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# CC434 Roach Building, 800 Rose Street, Lexington, KY 40536-0093
Data Availability
All data and results presented here are available in a FigShare repository: DOI: 10.6084/m9.figshare.14199521 . This includes characterized peaks derived from Fourier transform mass spectra and all downstream analyses of these characterized peak lists.
Abbreviations
- NSCLC
- Non-Small Cell Lung Carcinoma
- SMIRFE
- Small Molecule Isotope Resolved Formula Enumeration
- SCD-1
- Stearoyl-CoA Desaturase-1
- ACAT-1
- Acetyl-CoA Acetyltransferase
- EGFR
- Epidermal Growth Factor Receptor
- ALK
- Anaplastic Receptor Tyrosine Kinase Gene
- PD-1
- Programmed cell Death protein 1
- PD-L1
- Programmed Death-Ligand 1
- HMDB
- Human Metabolite Database
- ICI
- Information-Content-Informed
- IMF
- Isotope-resolved Molecular Formula
- EMF
- Elemental Molecular Formula
- PCA
- Principal Component Analysis